The Psychedelic Medicine Association Journal Club
Log In To Watch the Recording
Log In To Register
*Exclusive for members.
Thursday, September 29th at 5 pm Pacific, 8 pm Eastern >> Log In To Watch the Recording >>
Watch the NEW Offering for Members of The Psychedelic Medicine Association:
The Psychedelic Medicine Association Journal Club
Host:
Kate Pate, PhD
CEO & Founder, The Way Back & Coruna Medical; Board Member, Psychedelic Medicine Association
Dr. Kate Pate is a PhD neurophysiologist and Founder and CEO of The Way Back, a company that provides education and coaching services related to military, veteran, and first responder health. Within these communities, she advocates for functional and non-traditional approaches to healing, which can include psychedelic medicines when appropriate. She is also the Founder and CEO of Coruna Medical, a military-specific medical device company that creates innovative solutions for administering medical care in austere environments. Kate is a Board Member of the Psychedelic Medicine Association and part of the Medical Advisory and Research Team for HunterSeven Foundation. Select previous roles include serving as the Director of Research and Integration Coach for the Heroic Hearts Project, Research Advisor for Unlimited Sciences, and Assistant Professor of Physiology and Director of Research at Rocky Vista University’s College of Osteopathic Medicine. The areas of research she’s most passionate about include traumatic brain injury, neuroinflammation, and mental health.
Panelists:
Evan Wood, MD, PhD, FASAM, FRCPC
Chief Medical Officer at Numinus
Dr. Evan Wood has published over 650 peer-reviewed scientific articles and made major contributions to the establishment of innovative policy and therapeutic programs. Early in his career, Dr. Wood’s research contributed to revision of international guidelines for the treatment and prevention of HIV infection among persons who use drugs. Subsequently, he led efforts that have contributed to the regulation of adult cannabis use in Canada, the establishment of supervised injecting facilities as a standard of care for overdose prevention in Canada, and clinical therapeutic guidelines for a range of substance use disorders. Dr. Wood developed one of North America’s largest addiction medicine eduction programs and has been a Tier 1 Canada Research Chair and Professor of Medicine. As Numinus’ Chief Medical Officer, Dr. Wood is responsible for planning clinical research, assisting with protocol development, and clinical strategy within the organization.
Dr. Rick Barnett, PsyD
Co-Founder of Psychedelic Society of Vermont
Dr. Rick is a licensed clinical psychologist, licensed addictions counselor, and holds a Master's degree in clinical psychopharmacology. He founded and is CEO of CARTER, Inc (501c3 organization to address addiction), runs a private group general mental health and addiction group practice, and is co-founder of the Psychedelic Society of Vermont. Rick has been trained by MAPS for MDMA-Assisted Psychotherapy and completed a year-long psychedelic research and treatment program through the California Institute for Integral Studies. Rick offers Ketamine-Based Psychotherapy to select patients in his private practice. He has also serves on several boards with Vermont State Government, the Vermont Psychological Association, and the American Psychological Association. In addition, Rick has been in recovery from addiction for nearly 30 years and is an active advocate for recovery from addictions.
Kevin Franciotti, MA, LAC
Therapist & Psychedelic Program Director at Ballen Medical & Wellness
Kevin Franciotti is a Master’s-level therapist and Licensed Addiction Counselor, writer, and recovery advocate based in Denver. He is a former advisory board member for Project New Day foundation’s inaugural community-engaged public health project, Psychedelics in Recovery: Outreach and Service, focusing on support for mutual aid groups with members who integrate psychedelic experiences for ongoing addiction recovery. In 2011, Kevin underwent treatment for opioid use disorder with ibogaine, a drug derived from the iboga shrub indigenous to west-central Africa. He has previously written about his experience in various publications, including New Scientist magazine and TheFix.com.
At the Psychedelic Medicine Association, we’re always looking for ways to provide you even more value – both in education on psychedelics and in networking with your fellow members. So to this end, we’re bringing you the Psychedelic Medicine Journal Club!
As many of you may have experienced during school or residency, journal club is a gathering where all attendees read the same journal article and discuss it in depth to provide an even greater understanding of the material (all while getting to know each other even better).
If you attended our December meet and greet last year, this will be the same format: cameras on (if you wish!) and interactive, with someone from the PMA board (or other volunteers!) helping facilitate the discussion.
These journal clubs will be separate from our monthly webinar panels, but for our first-ever journal club, we wanted to do a special launch event on our normal webinar night so that everyone can get a taste of the journal club action!
For our inaugural journal club, facilitated by Dr. Kate Pate, we discussed “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial” which appeared in JAMA Psychiatry in August 2022.